Last reviewed · How we verify
Yimitasvir Phosphate Capsule
At a glance
| Generic name | Yimitasvir Phosphate Capsule |
|---|---|
| Also known as | DAG181 |
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD (PHASE1)
- To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects (PHASE1)
- Phase 2 Study of Yimitasvir Phosphate Capsules (PHASE2)
- Phase 3 Study of Yimitasvir Phosphate Capsules (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yimitasvir Phosphate Capsule CI brief — competitive landscape report
- Yimitasvir Phosphate Capsule updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI